Hims & Hers Health, Inc. is a consumer-first digital health and wellness platform launched in 2017 that connects patients with licensed healthcare professionals for telehealth consultations and personalized treatment plans. The company offers prescription generic, brand-name, and compounded medications for chronic conditions including sexual health, hair loss, hormone health, weight loss, dermatology, and mental health, with prescriptions fulfilled through its wholly-owned pharmacies. It also sells over-the-counter drug and device products, cosmetics, and supplements, some of which are white-labeled or co-branded, as well as comprehensive laboratory testing services. Many offerings are sold on a subscription basis through websites and mobile applications, which also provide educational programs and wellness content. The company serves customers in the United States, Canada, the United Kingdom, and the European Union, specifically in Germany, Ireland, France, and Spain. Its integrated technology stack supports the entire customer journey from discovery and purchase to clinical management and order fulfillment.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Healthcare Plans Homepage hims.com
Sector Healthcare IR page investors.hims.com
Tags
telehealth, digital health, sexual health, hair loss, hormone health, weight loss, dermatology, mental health, laboratory testing, subscription model, online pharmacy, consumer wellness, Hims & Hers
Press page —

Metrics

Valuation  
Market cap $ 4.333B
Market cap (USD) $ 4.333B
P/E -22.33
PEG —
P/BV 12.19
P/S 1.51
P/OCF 24.05
P/FCF 526.97
Dividend yield —
Turnover / mcap —
Returns  
ROE 25.2%
ROI 8.5%
ROIC 7.0%
Profit margin 5.5%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 179.8%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 31
Quality score 23.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue 2.348B 1.477B 872M 526.916M 271.878M —
Net profit 128.365M 126.038M -23.546M -65.678M -107.659M -3.049M
Free cash flow 57.406M 198.284M 46.991M -33.778M -39.419M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 32.47 24.18 8.9 6.41 6.55 14.6
Price performance 12m 0.34 1.72 0.39 -0.02 -0.55 0.47

Filed figures

Figure Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — 1.1M 4.1M 3.9M 6.7M 6.1M 32.1M
↳ YoY growth +272.7% -4.9% +71.8% -9.0% +426.2%
↳ 5y CAGR +96.3%
Lease liabilities (USD) — — 0.00 5.48M 5.31M 9.95M 11.3M 148M
Cash and deposits (USD) 41.7M 1.51M 1.06M 71.8M 46.8M 96.7M 221M 229M
Intangible assets (USD) — — 59,000 25.9M 21.8M 18.6M 43.4M 196M
Right-of-use assets (USD) — — 0.00 5.11M 4.94M 9.59M 10.9M 137M
Cash flow detail
Operating cash flow (USD) — -74.9M -777,074 -34.4M -26.5M 73.5M 251M 300M
Purchases of property, plant and equipment (USD) — — — — -7.2M -26.5M -52.8M -243M
Purchases of intangible assets (USD) — -1.48M -2.5M -4.18M -4.53M -9.27M -11.1M -16.5M
Change in inventories (cash effect) (USD) — -522,000 674,000 -9.63M -8M -902,000 -41.6M -13.7M
Change in payables (cash effect) (USD) — -6.08M -6,645 9.85M 12.7M 7.32M 43.7M 30.3M
Share buybacks (cash effect) (USD) — 0.00 0.00 -22M 0.00 -2M -83M -90M
Interest paid (cash effect) (USD) — -361,000 -10,000 0.00 0.00 — — —
Income taxes paid (cash effect) (USD) — -139,000 -221,000 -338,000 -636,000 -1.11M -7.92M -23.2M
Share-based compensation (USD) — 8.03M 5.83M 67.2M 42.8M 66.1M 92.3M 135M
Free cash flow (OCF - PPE - intangibles) (USD) — — — — -38.3M 37.7M 187M 40.9M
Income detail
Total comprehensive income (USD) — -72.1M -18.1M -108M -65.8M -23.4M 126M 131M
Comprehensive income to owners (USD) — -72.1M -18.1M -108M -65.8M -23.4M 126M 131M
Reported Feb 24, 2022 Feb 24, 2022 Feb 24, 2022 Feb 24, 2022 Feb 24, 2025 Feb 24, 2025 Feb 24, 2025 Feb 23, 2026

Operating KPIs — quarters

KPI Sep 24 Dec 24 Mar 25 Jun 25 Sep 25 Dec 25 Mar 26 Jun 26
Paid subscribers 2.05M 2.23M 2.37M 2.44M 2.47M 2.51M 2.58M 2.89M
↳ YoY growth (computed) +43.5% +38.4% +30.8% +20.7% +12.7% +9.2% +18.5%
↳ YoY growth (company-stated) +44.0% +31.0% +21.0%
Reported Nov 4, 2024 Feb 23, 2026 May 5, 2025 Aug 4, 2025 Nov 3, 2025 Feb 23, 2026 May 11, 2026 Aug 10, 2026

Operating KPIs — years

KPI Dec 2023 Dec 2024 Dec 2025
Paid subscribers — 2.23M 2.51M
↳ YoY growth +12.7%
Order intake (USD) 8.68M 10.5M —
↳ YoY growth +20.6%
Reported Feb 26, 2024 Feb 23, 2026 Feb 23, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Revenue of approximately $890 million, up 49% year-over-year in Q3 2026

Subscribers grew to nearly 2.8 million, up 13% year-over-year in Q3 2026

Tightens full year 2026 revenue guidance to a range of $3.13 billion to $3.15 billion and reduces Adjusted EBITDA guidance to a range of $257 million to $277 million

SAN FRANCISCO, November 9, 2026 – Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading global health and wellness platform, today announced financial results for the third quarter ended September 30, 2026.

“In healthcare, whoever owns the customer relationship wins, and that’s exactly what we’re building toward at Hims & Hers. Today, customers want real choice, real value, and a care team that knows them,” said Andrew Dudum, co-founder and CEO. “Everything we’re doing, from expanding the treatments and specialties we make available, to rolling out an AI-native experience to support every customer’s care, informed by leading minds in health and science, is designed to meet that higher bar. The platform people can rely on for their health every day, in every category, and every market, is the platform that will transform the industry.

November 6, 2026

Agreement gives patients a path to FDA-approved treatments at self-pay price through the Hims & Hers platform

INDIANAPOLIS--(BUSINESS WIRE)-- Eli Lilly and Company (NYSE: LLY) and Hims & Hers Health, Inc. (NYSE: HIMS) today announced an agreement to help expand access to Zepbound (tirzepatide) and Foundayo (orforglipron). Through the agreement, eligible patients who receive a prescription from a licensed provider on the Hims & Hers platform will access the same self-pay prices available to any patient without leaving the Hims & Hers platform.

The agreement brings together Lilly’s obesity medicines and Hims & Hers’ consumer platform. Patients can complete a consultation, receive a prescription if their provider determines it is appropriate, and have an FDA-approved Lilly medicine shipped directly to their home, all in one seamless experience. Self-pay pricing starts at $149 per month for Foundayo and $299 per month for Zepbound.

“At Lilly, we are always looking for new ways to help more people get the medicines they need, and that means meeting patients where they already are,” said Ilya Yuffa, Executive Vice President and President, Lilly USA and Global Customer Capabilities, Eli Lilly and Company. “Millions of people turn to Hims & Hers for their care, and through this agreement, those patients now have a simple, more direct way to get FDA-approved Lilly medicine at an affordable price if prescribed.”

Adults with obesity have shown strong and growing interest in getting care, including prescription medicines, through telehealth providers, especially as a broader range of FDA-approved GLP-1 treatments—including Lilly’s daily oral medicine, Foundayo—have become available. This agreement between Lilly and Hims & Hers helps expand access to patients who choose to seek care through one of the largest digital health platforms in the world.

“Lilly is one of the most innovative pharmaceutical companies in history, and I’m incredibly proud that Hims & Hers is a part of making sure more people can access the medicines they’ve created,” said Andrew Dudum, co-founder and CEO of Hims & Hers. “By working together, we’re not just reaching more people with obesity with seamless, personal access to FDA-approved Lilly medicine. We’re showing the industry what innovators can achieve for customers everywhere when we work together to make the world well.”

Hims & Hers supports customers through their entire health journey, from their very first question to their clinical treatment and continued follow-up care. Its technology platform supports provider outreach, follow-up care, and treatment planning. Weight loss patients on Hims & Hers receive a membership experience that includes 24/7 access to a care team, nutrition guidance, regular clinical check-ins, and access to the Hims & Hers Weight Loss community.

Hims & Hers has never offered access to compounded copies of Lilly’s GLP-1s, and has committed not to do so in the future. Additionally, as part of the agreement, the companies have committed to protecting independent clinical decision-making, so that providers on the Hims & Hers platform continue to prescribe the treatment they determine is right for each patient.

About Lilly

Lilly is a medicine company turning science into healing to make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer’s disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news , or follow us on Facebook , Instagram , and LinkedIn .

About Hims & Hers

Hims & Hers is a leading global health and wellness platform on a mission to help the world feel great through the power of better health. Hims & Hers connects consumers to licensed healthcare professionals, enabling them to access personalized treatments for conditions related to weight loss, mental health, sexual health, dermatology and more. For more information, visit www.himsandhershealth.com .

ZEPBOUND INDICATIONS AND SAFETY SUMMARY WITH WARNINGS

Zepbound_®_ (ZEHP-bownd) is an injectable prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with:

  • obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off.
  • moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA.

Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. It is not known if Zepbound is safe and effective for use in children.

Warnings - Zepbound may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.

  • Do not use Zepbound if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC).
  • Do not use Zepbound if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
  • Do not use Zepbound if you have had a serious allergic reaction to tirzepatide or any of the ingredients in Zepbound.

KwikPen_®_: Do not share your KwikPen with other people, even if the pen needle has been changed. You may give other people a serious infection or get a serious infection from them.

Zepbound may cause serious side effects, including:

Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Zepbound. Tell your healthcare provider if you have stomach problems that are severe or will not go away.

Dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away.

Gallbladder problems. Gallbladder problems have happened in some people who use Zepbound. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools.

Inflammation of the pancreas (pancreatitis). Stop using Zepbound and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. You may feel the pain from your abdomen to your back.

Serious allergic reactions. Stop using Zepbound and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.

Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Zepbound with medicines that can cause low blood sugar, such as a sulfonylurea or insulin.

Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness or feeling jittery.

Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Zepbound.

Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Zepbound may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking Zepbound before you are scheduled to have surgery or other procedures.

Common side effects

The most common side effects of Zepbound include nausea, diarrhea, vomiting, constipation, stomach (abdominal) pain, indigestion, injection site reactions, feeling tired, allergic reactions, belching, hair loss_,_ and heartburn. These are not all the possible side effects of Zepbound. Talk to your healthcare provider about any side effect that bothers you or doesn't go away.

Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch .

Before using Zepbound

  • Your healthcare provider should show you how to use Zepbound before you use it for the first time.
  • Talk to your healthcare provider about low blood sugar and how to manage it. Tell your healthcare provider if you are taking medicines to treat diabetes including an insulin or sulfonylurea.
  • If you take birth control pills by mouth, talk to your healthcare provider before you use Zepbound. Birth control pills may not work as well while using Zepbound. Your healthcare provider may recommend another type of birth control for 4 weeks after you start Zepbound and for 4 weeks after each increase in your dose of Zepbound.

Review these questions with your healthcare provider:

  • Do you have other medical conditions, including problems with your pancreas, or severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food?

  • Do you take diabetes medicines, such as insulin or sulfonylureas?

  • Do you have a history of diabetic retinopathy?

  • Are you scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)?

  • Do you take any other prescription medicines or over-the-counter drugs, vitamins, or herbal supplements?

  • Are you pregnant, plan to become pregnant, breastfeeding, or plan to breastfeed? Zepbound may harm your unborn baby. Tell your healthcare provider if you become pregnant while using Zepbound. Zepbound may pass into your breast milk. You should talk with your healthcare provider about the best way to feed your baby while using Zepbound.

  • Pregnancy Exposure Registry: There is a pregnancy exposure registry for women who have taken Zepbound during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry, or you may call 1-844-524-0039 or email at [email protected] or visit https://pregnancyregistry.lilly.com/zepbound .

How to take

  • Read the Instructions for Use that come with Zepbound.
  • Use Zepbound exactly as your healthcare provider says.
  • Use Zepbound with a reduced-calorie diet and increased physical activity.
  • Inject Zepbound under the skin (subcutaneously) of your stomach (abdomen), thigh, or have another person inject in the back of the upper arm. Do not inject ZEPBOUND into a muscle (intramuscularly) or vein (intravenously).
  • Use Zepbound 1 time each week, at any time of the day.
  • Change (rotate) your injection site with each weekly injection. Do not use the same site for each injection.

If you take too much Zepbound, call your healthcare provider, call the Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.

Zepbound is approved as a 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg injection.

Learn more

Zepbound is a prescription medicine. For more information, call 1-800-LillyRx (1-800-545-5979) or go to www.zepbound.lilly.com .

This summary provides basic information about Zepbound but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your healthcare provider. Be sure to talk to your healthcare provider about Zepbound and how to take it. Your healthcare provider is the best person to help you decide if Zepbound is right for you.

ZP CON BS 01SEP2026

FOUNDAYO INDICATION AND SAFETY SUMMARY WITH WARNINGS

Foundayo (fown-DAY-oh) is a prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off.

  • Foundayo should not be used with other GLP-1 receptor agonist medicines.
  • It is not known if Foundayo is safe and effective for use in children.

Warnings – Foundayo may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.

  • Do not use Foundayo if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC).
  • Do not use Foundayo if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
  • Do not use Foundayo if you have had a serious allergic reaction to orforglipron or any of the ingredients in Foundayo.

Foundayo may cause serious side effects, including:

Inflammation of the pancreas (pancreatitis). Stop taking Foundayo and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. Sometimes you may feel the pain from your abdomen to your back.

Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Foundayo. Tell your healthcare provider if you have stomach problems that are severe or will not go away.

Dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away.

Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Foundayo with medicines that can cause low blood sugar, such as an insulin or sulfonylurea. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness, or feeling jittery.

Serious allergic reactions. Stop using Foundayo and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.

Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Foundayo.

Gallbladder problems. Gallbladder problems have happened in some people who use Foundayo. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools.

Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Foundayo may increase the chance of food getting into your lungs during surgery or other procedures. Tell your healthcare providers that you are taking Foundayo before you are scheduled to have surgery or other procedures.

Common side effects

The most common side effects of Foundayo include nausea, constipation, diarrhea, vomiting, indigestion, stomach (abdominal) pain, headache, swollen belly, feeling tired, belching, heartburn, gas, and hair loss. These are not all the possible side effects of Foundayo. Talk to your healthcare provider about any side effect that bothers you or doesn't go away.

Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch .

Before taking Foundayo

  • Tell your healthcare provider about all the medicines you take. Foundayo may affect the way some medicines work, and some medicines may affect the way Foundayo works.
  • Pregnancy Exposure Registry: There will be a pregnancy exposure registry for women who have taken Foundayo during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry, or you may contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979).
  • If you take birth control pills by mouth, talk to your healthcare provider before you take Foundayo. Birth control pills may not work as well while taking Foundayo. Your healthcare provider may recommend another type of birth control for 30 days after starting Foundayo and for 30 days after each dose increase of Foundayo.
  • Talk to your healthcare provider about low blood sugar and how to manage it. Tell your healthcare provider if you are taking medicines to treat diabetes including an insulin or sulfonylurea.

Review these questions with your healthcare provider:

  • Do you have other medical conditions, including problems with your pancreas or kidneys, or severe problems with your liver, severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food?
  • Do you have a history of diabetic retinopathy?
  • Are you scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)?
  • Are you pregnant or plan to become pregnant? Foundayo may harm your unborn baby.
  • Are you breastfeeding or plan to breastfeed? Breastfeeding is not recommended during treatment with Foundayo.
  • Do you take any other prescriptions or over-the-counter medicines, vitamins, or herbal supplements?

How to take

  • Take Foundayo exactly as your healthcare provider tells you to.
  • Use Foundayo with a reduced-calorie diet and increased physical activity.
  • Take Foundayo by mouth 1 time each day, with or without food.
  • Swallow tablets whole. Do not break, crush, or chew the tablet.
  • If you miss a dose, take it as soon as possible. Do not take 2 doses of Foundayo in the same day.
  • Do not take more than 1 tablet per day.
  • If you miss taking Foundayo for 7 or more days in a row, call your healthcare provider to talk about how to restart your treatment.
  • If you take too much Foundayo, call your healthcare provider or Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.

Learn more

Foundayo is a prescription medicine available in 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, or 17.2 mg oral tablets. For more information, call 1-800-545-5979 or go to foundayo.lilly.com .

This summary provides basic information about Foundayo but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your doctor. Be sure to talk to your doctor or other healthcare provider about Foundayo and how to take it. Your doctor is the best person to help you decide if Foundayo is right for you.

OG CON BS APR2026

Foundayo_™_ is a trademark of Eli Lilly and Company.

Lilly Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about an agreement between Lilly and Hims & Hers to help expand access to Zepbound (tirzepatide) and Foundayo (orforglipron) to eligible patients who receive a prescription from a licensed provider via the Hims & Hers platform and reflects Lilly’s current beliefs and expectations. However, there can be no assurance that the agreement will be implemented as anticipated, that the parties will realize its expected benefits, or that Lilly will execute its strategy as planned. For further discussion of risks and uncertainties relevant to Lilly’s business that could cause actual results to differ from Lilly’s expectations, see Lilly’s Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

Hims & Hers Cautionary Statement Regarding Forward-Looking Statements

Cautionary Note Regarding Forward-Looking Statements:

This communication includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes,” “estimates,” “anticipates,” “expects,” “intends,” “plans,” “assume,” “may,” “will,” “likely,” “potential,” “projects,” “predicts,” “continue,” “goal,” “strategy,” “future,” “forecast,” “target,” “outlook,” “opportunity,” “project,” “confidence,” “foundation,” “groundwork,” or “should,” or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, statements regarding the agreement between Eli Lilly and Company and Hims & Hers, including the availability of Zepbound (tirzepatide) and Foundayo (orforglipron) on the Hims & Hers platform, related self-pay pricing, and the potential effects of the agreement on customers and Hims & Hers’ business. These statements are based on management’s current expectations, but actual results may differ materially due to various factors.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained in this communication are based on Hims & Hers’ current expectations, assumptions and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Hims & Hers’ control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the timing and logistical considerations related to the integration and rollout of Lilly medications on Hims & Hers’ platform, and the related customer response; Hims & Hers’ ability to perform under and maintain the agreement with Lilly, including with respect to pricing, fulfillment, and Hims & Hers’ commitments; and changes in the application, interpretation, and enforcement of healthcare, pharmacy, telehealth, consumer protection, or privacy laws or regulations applicable to our business, including those relating to prescription GLP-1 medications; and other factors described in the Risk Factors and other sections of Hims & Hers’ most recently filed Quarterly Report on Form 10-Q, Hims & Hers’ most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time with the Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should any of Hims & Hers’ assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The forward-looking statements contained in this communication are made only as of November 6, 2026. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that Hims & Hers’ actual results may differ materially from those made in or suggested by the forward-looking statements contained in this communication.

**Hims & Hers Press Contact:
**Abby Reisinger-Moley
[email protected]

**Eli Lilly and Company Press Contact:
**Michael Jamison
[email protected]

Source: Hims & Hers

Multimedia Files:

View All News

Investors

November 5, 2026

The program now includes 14 partners, with new savings on health insights, at-home strength training, daily nutrition, and air medical transport

SAN FRANCISCO--(BUSINESS WIRE)-- Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced four new partners joining Hims & Hers Benefits : Grüns ®, Medjet ®, Tonal ™, and Viome ™. The program launched in March with two partners and has grown to include 14, with benefits designed to support subscribers’ whole-body health, including through a GLP-1 weight loss journey.

"Building health is an everyday activity. It starts with understanding your body and continues with the right support as it changes, from the strength and nutrition that can complement GLP-1 treatment to knowing you’re covered when you need it most," said Dheerja Kaur, Chief Product Officer at Hims & Hers. "Hims & Hers Benefits brings that support together in one place, so our subscribers can access the tools behind their whole-body health at prices that make a real difference.”

New benefits accessible to subscribers include:

  • Simplify daily nutrition with Grüns. When GLP-1 treatment changes how much you eat, getting the nutrition you need from food alone can take more effort. Grüns combines more than 60 ingredients, including vitamins, minerals, and prebiotic fiber, into daily gummy packs designed to make comprehensive nutrition a habit that’s easy to keep. Subscribers can receive $30 off their first order.*
  • Get support when you need it most with Medjet. Medjet is an air medical transport membership for travelers. If you’re hospitalized 150 or more miles from home, Medjet arranges transport to the hospital of your choice in your home country, so you can recover close to your own doctors and family. MedjetHorizon adds 24/7 security and crisis response services. Subscribers can receive approximately 30% off Medjet’s standard retail rates, with MedjetAssist memberships for $215/yr (individual) or $295/yr (family) and MedjetHorizon memberships for $390/yr (individual) or $485/yr (family).*
  • Build strength at home with Tonal. Tonal 2 is an AI-powered home strength system that uses motor-driven digital weight in place of plates and dumbbells, with real-time form feedback and programs that adapt as you get stronger. Strength training can be a powerful complement to GLP-1 treatment, and Tonal brings it into your living room. Subscribers can receive $1,000 off Tonal 2 hardware.*
  • Make every bite count with Viome. When you’re eating less, what you eat matters more. Whether you’re beginning a GLP-1 journey or navigating changes along the way, Viome’s Full Body Intelligence™ test provides personalized insights into your microbiome and how your body reacts to your diet. Using RNA sequencing of samples you collect at home, it looks at how your body functions as it changes and delivers personalized food and supplement recommendations to help you make more intentional choices about your nutrition. Subscribers can receive $100 off Full Body Intelligence™ and one free month of Viome Precision Supplements™ with the purchase of two months.*

“So many people already have nutritional gaps, and on a GLP-1, eating less can make good nutrition even harder to keep up with,” said Aaron Jones, Chief Marketing Officer at Grüns. “We’re excited to help Hims & Hers subscribers make daily nutrition something they look forward to.”

“Illness and injury while traveling are things you hope never happen," said John Gobbels, CEO of Medjet. “By partnering with Hims & Hers, we’re helping more people travel knowing that if the unexpected does occur, they can get to a hospital they trust, close to home.”

“Every health journey is different, but strength belongs in all of them,” said Derek Mellencamp, Chief Revenue Officer at Tonal. “It’s the foundation for how you move, how you feel, and how well you can live for years to come. Tonal tracks your progress every step of the way, so you can see and feel yourself getting stronger. With Hims & Hers as a partner, that progress is in reach for many more people.”

"There’s no one-size-fits-all approach to nutrition, especially as your body’s needs evolve. Viome was built to help individuals better understand their unique nutritional requirements and make it easier to take meaningful actions to improve their health. Through Hims & Hers Benefits, more subscribers can get access to personalized nutrition recommendations and fill their nutrition gaps with supplements formulated for their body’s needs," said Shannon Pappas, President of Consumer Business at Viome.

Underpinning the company's commitment to put its customers first, Hims & Hers does not profit from these benefits. Instead, 100% of the negotiated benefits are passed directly to active subscribers.

*See full terms and conditions at hims.com/benefits and forhers.com/benefits. Partner benefits are immediately available to active Hims & Hers subscribers only. Some offers include free trials or introductory pricing. See partner's website for full terms. Prescription products not included; provider consultation required. Offers subject to change. All third-party brand names and logos are trademarks of their respective owners.

About Hims & Hers Health, Inc.

Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That's why we're building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health and wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.hims.com and www.forhers.com .

Press Contact
Susan Cadrecha
[email protected]

Source: Hims & Hers

Multimedia Files:

View All News

Investors

Prompts

Hims & Hers Health, Inc. (ticker HIMS), listed in United States.

Company History

Date Change Detail
Nov 19, 2020 Renamed OAKTREE ACQUISITION CORP. → HIMS & HERS HEALTH, INC.

ETFs Holding Hims & Hers Health, Inc.

ETF Weight in ETF Shares Market value As of
KYLD 3.70% 60,720 $ 1.796M Aug 31, 2026
PSC 1.31% 877,347 $ 30.418M Jun 30, 2026
MKTN short -0.91% -28,077 $ -973.43K Jun 30, 2026
BTAL short -0.53% -43,516 $ -1.509M Jun 30, 2026
FSEG 0.29% 477 $ 16.538K Jun 30, 2026
SAGP 0.24% 5,377 $ 186.421K Jun 30, 2026
FTKI 0.13% 1,793 $ 33.278K Nov 16, 2026
SCDS 0.10% 508 $ 8,915.40 Nov 17, 2026
JMEE 0.06% 105,089 $ 1.844M Nov 17, 2026
DFAS 0.04% 702,762 $ 13.865M Nov 12, 2026
MSSM 0.04% 9,032 $ 267.167K Aug 31, 2026
RILA 0.03% 497 $ 13.802K Jul 31, 2026
AVMC 0.03% 8,350 $ 154.976K Nov 16, 2026
JGRO 0.02% 88,265 $ 1.549M Nov 17, 2026
MSLC 0.01% 15,470 $ 457.603K Aug 31, 2026
AVUS 0.01% 39,967 $ 741.788K Nov 16, 2026
IALT short -0.01% -58,986 $ -1.095M Nov 16, 2026
AVLC 0.01% 8,149 $ 151.245K Nov 16, 2026
FESM 0.00% 138 $ 4,784.46 Jun 30, 2026
AVSC 0.00% 5,000 $ 92.8K Nov 16, 2026
AVSU 0.00% 1,164 $ 21.604K Nov 16, 2026